Immunotherapy in Advanced Non-Small Cell Lung Cancer: About Two Case Reports Imunoterapia no Cancro do Pulmão de Não Pequenas Células Doença Avançada: A Propósito de Dois Casos Clínicos

Abstract

In light of current knowledge, the treatment with immunotherapy in advanced non-small cell lung cancer disease presents thebest results in patients with programmed death ligand 1 (PD-L1) + expression. We present two different clinical cases, both successful: the first refers to a 91-year-old male patient with 90% PD-L1 expression and high response rate to the treatment of immunotherapy with pembrolizumab at a dose of 200 mg every 3 weeks; in the second case, a 47-year-old female with PD-L1 negative expression and in whom immunotherapy was used as second line after progression under chemotherapy treatment and who also had a complete response with the use of atezolizumab at the dose of 1200 mg every 3 weeks.